| 17.56 -0.1 (-0.57%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.38 | 1-year : | 24.97 |
| Resists | First : | 18.3 | Second : | 21.38 |
| Pivot price | 15.78  |
|||
| Supports | First : | 15.72 | Second : | 14.11 |
| MAs | MA(5) : | 17.57 |
MA(20) : | 15.57 |
| MA(100) : | 13.05 |
MA(250) : | 0 | |
| MACD | MACD : | 0.8 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 80.4  |
D(3) : | 83.5 |
| RSI | RSI(14): 70.1 |
|||
| 52-week | High : | 18.3 | Low : | 2.21 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PHAT ] has closed below upper band by 17.2%. Bollinger Bands are 125.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.76 - 17.85 | 17.85 - 17.92 |
| Low: | 17.15 - 17.24 | 17.24 - 17.32 |
| Close: | 17.42 - 17.57 | 17.57 - 17.69 |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Wed, 24 Dec 2025
Phathom Pharmaceuticals (NASDAQ:PHAT) Hits New 52-Week High - Here's What Happened - MarketBeat
Tue, 23 Dec 2025
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Is Expected To Breakeven In The Near Future - Yahoo Finance
Thu, 18 Dec 2025
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 1-Year High - What's Next? - MarketBeat
Fri, 12 Dec 2025
Phathom Pharmaceuticals stock hits 52-week high at $16.27 - Investing.com
Fri, 21 Nov 2025
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth (NASDAQ:PHAT) - Seeking Alpha
Tue, 04 Nov 2025
Phathom Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 87.7 (%) |
| Shares Short | 12,740 (K) |
| Shares Short P.Month | 13,570 (K) |
| EPS | -3.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.95 |
| Profit Margin | -186.6 % |
| Operating Margin | -30.9 % |
| Return on Assets (ttm) | -42.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 202.6 % |
| Gross Profit (p.s.) | 1.8 |
| Sales Per Share | 2.06 |
| EBITDA (p.s.) | -3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -225 (M) |
| Levered Free Cash Flow | -154 (M) |
| PE Ratio | -4.68 |
| PEG Ratio | 0 |
| Price to Book value | -2.96 |
| Price to Sales | 8.48 |
| Price to Cash Flow | -5.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|